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Abstract
Background: The incidence of ventilator-associated pneumonia (VAP) within the first 48 hours of intensive care
unit (ICU) stay has been poorly investigated. The objective was to estimate early-onset VAP occurrence in ICUs
within 48 hours after admission.
Methods: We analyzed data from prospective surveillance between 01/01/2001 and 31/12/2009 in 11 ICUs of Lyon
hospitals (France). The inclusion criteria were: first ICU admission, not hospitalized before admission, invasive
mechanical ventilation during first ICU day, free of antibiotics at admission, and ICU stay ≥ 48 hours. VAP was
defined according to a national protocol. Its incidence was the number of events per 1,000 invasive mechanical
ventilation-days. The Poisson regression model was fitted from day 2 (D2) to D8 to incident VAP to estimate the
expected VAP incidence from D0 to D1 of ICU stay.
Results: Totally, 367 (10.8%) of 3,387 patients in 45,760 patient-days developed VAP within the first 9 days. The
predicted cumulative VAP incidence at D0 and D1 was 5.3 (2.6-9.8) and 8.3 (6.1-11.1), respectively. The predicted
cumulative VAP incidence was 23.0 (20.8-25.3) at D8. The proportion of missed VAP within 48 hours from
admission was 11% (9%-17%).
Conclusions: Our study indicates underestimation of early-onset VAP incidence in ICUs, if only VAP occurring ≥
48 hours are considered to be hospital-acquired. Clinicians should be encouraged to develop a strategy for early
detection after ICU admission.
Background
The epidemiological surveillance of healthcare-associated
infections (HAIs) in intensive care units (ICUs) provides
clinicians and caregivers with trend descriptions and con-
tributes to HAI prevention [1-4]. When studies from
such epidemiological surveillance programs are carried
out, standardized definitions of risk factors for HAI must
be used. However, these distinctions as well as the termi-
nology adopted change over time. Indeed, in the last
Centers for Disease Control and Prevention definition,
HAI replaced the term “hospital-acquired infection” [5].
To exclude community-acquired infections, it was
acknowledged that a period of 48 hours between ICU
admission and the onset of symptoms was required to
identify cases as hospital-acquired infections [1-4,6-10].
The time window of 48 hours was first conceived by US
National Nosocomial Infection Surveillance (NNIS). The
NNIS/National Healthcare Safety Network retained this
value for bacterial infections because of their typical
incubation period [11]. However, the statement: 1) is
both conservative for some microorganisms with longer
incubation periods (i.e. Mycoplasma pneumonia) or
some viruses (i.e. influenza) and restrictive for others (i.e.
Streptococcus pneumoniae) [12], and 2) does not take
device exposure into account. In France, nosocomial
infection surveillance networks adopted this time period.* Correspondence: philippe.vanhems@chu-lyon.fr1Hospices Civils de Lyon, Infection Control Unit, Edouard Herriot Hospital,
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The main consequence is that HAIs occurring before the
second day after admission are not considered.
Early-onset, ventilator-associated pneumonia (VAP),
arising within 48 hours after device exposure, should be
designated as HAI [5]. However, very few data support
this view [13]. It has been noted that colonization of the
trachea in the first 24 hours after intubation occurs fre-
quently in head trauma patients and predicts the develop-
ment of early-onset pneumonia [14]. Because no data on
early-onset VAP are readily available, its incidence within
48 hours after ICU admission can be estimated from
observed VAP.
Additional assessment of the incidence of very early-
onset VAP is important to discuss these new definitions of
hospital-acquired VAP and to draw the attention of clini-
cians towards early adverse events. The primary objective
of the present study was to estimate the incidence of
early-onset VAP in ICUs within the first 48 hours after
admission.
Methods
Setting
Analysis was based on prospective data from 11 ICUs of
Lyon hospitals in France. These ICUs participate in a
national HAI surveillance network that has been described
in detail elsewhere [15]. Briefly, all ICU patients staying
48 hours or more were included in the surveillance pro-
gram until their ICU discharge. The data were collected
prospectively over the year on a standardized collection
form, which comprised demographic characteristics, the
severity of underlying diseases, risk factors for HAIs, expo-
sure to mechanical ventilation, central venous catheters,
urinary catheters, date and site of infection, etiological
agents, and patient outcome.
Informed consent was waived because data were
extracted from the surveillance database. According to
French law, a study like this one does not require ethics
committee approval because it is observational and based
on a surveillance database approved under national regula-
tions (Comité National Informatique et Liberté).
Inclusion criteria
Patients discharged between 01/01/2001 and 31/12/
2009, hospitalized ≥ 48 hours in ICUs, were included in
the present study if they met the following criteria: 1)
first ICU admission, 2) not admitted from hospital, 3)
free of antibiotics at the time of ICU admission, 4)
neither intubated nor tracheotomized at the time of
ICU admission, 5) intubated or tracheotomized during
the first 24 hours after ICU admission. Patients admitted
from other wards or undergoing tracheal intubation or
tracheotomy or antibiotics prior to ICU admission were
excluded.
Definitions of VAP
VAP [16] was defined according to the following:
- Chest X-rays exhibiting lung infiltrates;
- Temperature > 38°C or leukocyte count > 12,000/
mm3 or < 4,000/mm3;
- One of the following: 1) sputum modification, 2)
suggestive auscultation, 3) low oxyhemoglobin satura-
tion, or 4) increased pulmonary oxygen consumption;
- And 1 of the following: 1) directed bronchoalveolar
lavage (BAL)-positive culture at a threshold of 104 cfu/
ml in case of BAL or 103 cfu/ml in case of non-
bronchoscopic protected specimen brushing [17], or 2)
fiberoptic bronchoscopy specimen-positive culture at a
threshold of 106 cfu/ml, or 3) 1 of the following: posi-
tive pleural or blood cultures without any other site of
infection, pulmonary or pleural abscess, histopatholo-
gical evidence of pneumonia or cultures positive for
specific agents.
Microbiological specimens were always obtained before
the introduction of new antibiotics and as soon as possible
after the identification of clinical or radiological criteria of
pneumonia. In case of consecutive VAP episodes, only the
first episode was considered for analysis.
Statistical analysis
The primary end-point was the incidence of early-onset
VAP during ICU stay. Therefore, the follow-up period in
the present study was restricted from day 0 (D0, ICU
admission) to D8 of ICU stay. Patients were followed up
from admission to VAP occurrence or were censored at
the end of mechanical ventilation exposure or at D8 if no
VAP had transpired. The enrolled population was
described. At each day of this follow-up, the observed
number of incident VAP cases, the number of patients at
risk for that day, and the main characteristics of patients
who developed VAP were recorded. Because the exact
hour of the beginning of exposure was not evident, the
number of invasive mechanical ventilation days was
divided by 2 to estimate mechanical ventilation days at
the first and last days. The hypothesis was that, on aver-
age, patients were exposed to mechanical ventilation for
12 hours.
Categorical variables were compared by Chi2 test. Con-
tinuous variables, expressed as median and interquartile
range (IQR), were compared by the Mann-Whitney U
test. VAP incidence was expressed as the number of
events per 1,000 invasive mechanical ventilation days of
exposure and 95% confidence interval (CI).
Poisson regression was fitted to the data from D2 to D8
with the observed number of incident VAP as the depen-
dent variable. Time was included as an independent
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variable with the number of invasive mechanical ventila-
tion days at risk as offset in the model. The addition of a
quadratic term for time was tested with the likelihood
ratio test and conserved to take into account the non-
linearity of incidence with time. Predictions of early-
onset VAP incidence rates at D0 and D1 were based on
the final model fitted. This model also estimated missed
early-onset VAP occurring within 48 hours after admis-
sion. All tests were 2-tailed, p < 0.05 was considered sig-
nificant. The data were analysed with Stata 8.0 software
(Stats Corp. 2003. Stata Statistical Software: Release 8.
College Station, TX: StataCorp LP).
Results
Population characteristics
A total of 20,640 patients were included in the surveil-
lance in 11 ICUs over the study period. As a whole, 9,322
(45.2%) were newly hospitalized patients without
immediate previous hospital stay, 9,657 (47.8%) patients
did not receive antibiotics before admission, and 17,302
(83.8%) were exposed to mechanical ventilation on the
first day of ICU stay.
Overall, data on 3,387 patients (37.6% women),
accounting for 45,760 patient-days, were analyzed. A
total of 367 (10.8%) patients developed VAP within the
first 9 days of ICU stay. The main patient characteristics
are described in Table 1. Median age was 54.3 years (IQR
40-69 years), and median Simplified Acute Physiology
Score II was 44 (32-56). Totally, 914 (27.0%) were trauma
patients. Hospital mortality was 21.7%.
VAP incidence
The mean observed VAP incidence was 20.6 (95% CI
18.6-22.8) per 1,000 invasive mechanical ventilation
days. Table 2 reports the VAP microbiological findings.
Figure 1 depicts the distribution of observed and esti-
mated VAP. The predicted cumulative incidence of
early-onset VAP at D0 and D1 was 5.3 (95% CI 2.6-9.8)
and 8.3 (95% CI 6.1-11.1) per 1,000 invasive mechanical
ventilation days, respectively (Table 3). VAP incidence,
estimated by the Poisson model, was 23.0 (95% CI 20.8-
25.3) per 1,000 invasive mechanical ventilation days at
D8. The total proportion of missed early-onset VAP
during the first 48 hours of ICU stay was 11% (95% CI
9%-17%).
Discussion
The objective of the study was to estimate the incidence
of early-onset VAP shortly after admission in ICU. The
estimated incidence of early-onset VAP in ICUs within
48 hours after admission was 8.3 (95% CI 6.1-11.1) per
1,000 invasive mechanical ventilation days. It should be
noted that these results cannot be generalized to ICU
patient populations because patients were restricted to
those at high risk of VAP with mechanical ventilation
exposure and no antibiotic use at admission, which
might overestimate the daily incidence. Therefore, this
sample accounts for a population with high risk of VAP.
Indeed, patients who receive antibiotics before ICU
admission are at lower risk of VAP [18,19] or VAP within
48 hours after admission [13]. The same is true for
Table 1 Characteristics of patients with or without ventilator-associated pneumonia (VAP) within 9 days of ICU
admission in University of Lyon hospitals (France), January 2001-December 2009
Characteristics VAP within 9 days
(n = 367)
No VAP within 9 days (n = 3,020) p-value
Categorical variable, n (%)
Year of admission < 0.001
2001-2003 95 (25.9) 1,202 (39.8)
2004-2006 116 (31.6) 937 (31.0)
2007-2009 156 (42.5) 881 (29.2)
Gender, female 109 (29.7) 1,165 (38.6) 0.001
Neutrophil count < 500/mm3 23 (6.3) 189 (6.3) 1.0
Trauma 160 (43.6) 754 (25.0) < 0.001
Diagnosis category < 0.001
Medical 152 (41.5) 1,844 (61.1)
Surgical 214 (58.5) 1,176 (38.9)
Deceased in-hospital 75 (20.5) 656 (21.8) 0.6
Continuous variable, median (interquartile range)
Age, years 51 (36-66) 55 (40-69) 0.002
Simplified Acute Physiology Score 47 (36-56) 44 (32-56) 0.011
Length of hospital stay, days 21 (12-33) 5 (3-12) < 0.001
Length of intubation, days 15 (9-25) 2 (1-8) < 0.001
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previously-intubated patients whose VAP risk decreases
over time [20].
To the best of our knowledge, data on the incidence
of early-onset VAP are sparse. In a prospective study of
250 intubated ICU patients, 32 (12.8%) incurred VAP
within 48 hours [13]; among them, 18 had VAP within
24 hours. However, that study did not provide incidence
density, but focused on risk factors for pneumonia
within 48 hours of tracheal intubation. The microorgan-
ism that they isolated most frequently was Staphylococ-
cus aureus [13]; the same pattern was found for VAP in
our study within 9 days. However, Pseudomonas aerugi-
nosa, infrequent in our series, is a frequent etiological
microorganism in VAP [21].
In early-onset VAP, we cannot totally exclude the occur-
rence of community-acquired pneumonia in the incuba-
tion period before admission or early aspiration-associated
pneumonia at admission. VAP within 48 hours after
hospitalization might be related to the acute period of
mechanical ventilation, the severity of the underlying
disease or both. Later infections could be associated with
chronic exposure to mechanical ventilation and the evolu-
tion of the underlying disease. The distinction between
acute and chronic risks of VAP might lead to specific pre-
ventive measures [19]. In early-onset VAP, the bacteria
involved and the risk-factors for pneumonia might be
mostly related to the reason for admission. On the other
hand, late-onset VAP might be due more to the duration
of exposure to invasive mechanical ventilation, quality of
care or environmental ecology of the unit.
Our study has some limitations. First, no data were
available concerning nasogastric tubes and aspiration,
although patients with trauma could suffer aspiration
pneumonia. Also, we were unable to control for this risk
factor of pneumonia. However, the pathogens found most
frequently were not Gram-negative bacilli, which did not
suggest aspiration pneumonia. Second, the Glasgow coma
scale, which can help to distinguish between VAP and
aspiration pneumonia, was not available. Third, the exter-
nal validity of the results was limited by initial population
Table 2 Microbiological findings on patients who developed ventilator-associated pneumonia in ICUs of University of
Lyon hospitals (France), January 2001-December 2009
Microorganism, n (%) Day 2 (n = 50) Day 3 (n = 82) Day 4 (n = 77) Day 5 (n = 54) Day 6 (n = 31) Day 7 (n = 23) Day 8 (n = 23)
Staphylococcus aureus 18 (36) 35 (43) 28 (36) 23 (43) 19 (38) 8 (26) 6 (26)
Streptococcus pneumoniae 8 (16) 9 (11) 11 (14) 5 (9) 4 (8) 3 (10) 2 (9)
Haemophilus influenzae 10 (20) 14 (17) 16 (21) 14 (26) 9 (18) 4 (13) 3 (13)
Pseudomonas aeruginosa 3 (6) 1 (1) 5 (6) 5 (9) 2 (4) 3 (10) 5 (22)
Enterobacter 4 (8) 5 (6) 8 (10) 4 (7) 4 (8) 8 (26) 13 (39)
Others 18 (26) 24 (29) 17 (19) 16 (32) 10 (32) 4 (17) 2 (9)
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Figure 1 Observed and estimated number (95% confidence interval) of VAP calculated by the Poisson regression model during the
first 9 days of ICU stay in University of Lyon hospitals (France), January 2001-December 2009.
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selection. However, this selection permitted us to empha-
size the magnitude of the problem in patients with high
risk of VAP.
The results need to be confirmed in prospective stu-
dies with data on early-onset VAP. Ideally, a large pro-
spective investigation should be undertaken, including
patients since the first day of admission, the precise
time of exposure to mechanical ventilation as well as
nasogastric tubes. Such a study, with microbiological
and clinical data collection since the first day of admis-
sion, would permit differentiation between community-
and hospital-acquired infections. Our results should
encourage the surveillance of infection features shortly
after ICU admission. In this setting, increased clinical
monitoring and vigilance of early-onset VAP as well as
early epidemiological surveillance of HAIs should be
reinforced. Moreover, the identification of risk factors of
early VAP might be helpful to improve clinical care and
to prevent these infections.
Conclusions
In summary, our study suggests possible underestimation
of VAP incidence in ICUs. This finding should encourage
clinicians to develop a strategy for the quick detection of
early-onset VAP shortly after ICU admission. In such a
setting, active, early surveillance of VAP features might
improve clinical diagnosis and patient outcome. The eva-
luation of preventive measures against early-onset VAP,
immediately after device exposure, should be encouraged.
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